Yuhan USA and Huinno are teaming up to enter the US digital healthcare market with AI-driven ECG monitoring and clinical prediction solutions.

The collaboration centers on deploying Huinno’s MEMO Patch M, MEMO Cue, MEMO Care ECG monitoring tools, and the Vital-PICASO clinical prediction platform.

The strategic agreement covers US sales and marketing for MemoPatch M, MemoCue, MemoCare, and the Vital Picasso clinical prediction system.

The announcement was reported by Jeon Ji-woo.

Memo Patch M is an ultra-lightweight wearable ECG monitor providing up to eight days of continuous data and is defibrillation-proof to IEC 60601-1 Type CF, with FDA 510(k) clearance obtained last year.

Memo Patch M supports continuous eight-day monitoring and remains stable in high-risk clinical environments.

Memo Patch M is capable of eight-day continuous monitoring and has FDA 510(k) clearance, functioning reliably even in defibrillation environments.

Vital-PICASO, developed by HUINNO AIM, analyzes vital signs to predict major deteriorations like hypotension, hypoxia, and cardiac arrest, and was named an Innovative Medical Device by MFDS last year.

Vital-PICASO assesses patient vitals to forecast deterioration in advance and has been designated an Innovative Medical Device by Korea’s MFDS.

Vital Picasso predicts dangerous deterioration such as hypotension, hypoxia, and cardiac arrest before they occur.

Huinno CEO Gil Yeong-joon said the goal is to tailor solutions for the US and expand Huinno’s global digital health footprint to improve patient safety and clinical efficiency.

MemoCue is an AI telemetry tool that analyzes real-time inpatient ECG data to support rapid clinical decisions and integrates with hospital systems.